Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (20123)	5/9/1998 7:31:00 PM
From: WTDEC	Respond to of 32384

H, thanks for this bit of Progenx history. It filled in a void in my understanding. Hope my package arrived. Regards, Walter

To: Henry Niman who wrote (20123)	5/10/1998 11:32:00 AM
From: N	Read Replies (1) \| Respond to of 32384

Henry, If you don't mind, I have some questions here: I had been collaborating with Ron Evans and when CEO Howard Birndorf went to talk to him about joining Progenx's scientific advisory board, it became clear that Ron was interested in comercially developing his IR technology. Progenx exclusively licensed the technology from Salk and then switch from a cancer diagnositic company to a cancer therapeutics company and changed its name to Ligand. -- Is this correct: Progenx licensed Evan's IR technology from Salk? (line 3 and 4 from bottom) -- Where was Evans' academic position at that time? Was your research with him work joint with Salk? Or at Progenx? Is Evans currently an active academic? -- When were Progenx and, then, Ligand formed? Thank you. Nancy